Timber Pharmaceuticals, founded in 2019, is a dedicated medical dermatology brand focused on developing treatments for unmet needs in the field. With a particular emphasis on rare skin diseases or conditions that currently have no approved treatments, Timber aims to address the most neglected therapeutic areas in the pharmaceutical industry. There are over 450 different rare skin diseases that have been identified, yet only 17 FDA approvals have been granted for eight rare dermatological conditions since the Orphan Drug Act in 1983.

Timber Pharmaceuticals was formed through the collaboration of three companies, each with expertise in all phases of drug development and clinical research. The team consists of world-class advisors and a strong leadership team with a successful track record in advancing therapies for both rare and dermatologic diseases and conditions. Timber Pharmaceuticals is initially targeting multiple indications in rare/orphan dermatology with no approved treatments.

Their investigational therapies have proven mechanisms-of-action supported by decades of clinical experience, as well as well-established CMC (chemistry, manufacturing, and control) and safety profiles. For more information about Timber Pharmaceuticals, their focus, pipeline, investment opportunities, or to get in touch with them, visit their website